Japanese drugmaker Shionogi ( OTCPK:SGIOY ) said a Phase 3 study has shown its antiviral drug Xocova was effective in reducing the risk of developing symptomatic COVID-19 infection in those exposed to the disease. The Phase 3 study consisted of 2,400 participants.
Back to Health Page
